Eurand Overview

  • Year Founded
  • 1969

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 620

Employees

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 3

  • Investments
  • 2

Eurand General Information

Description

Manufacturer and developer of pharmaceutical and biopharmaceutical products. The company has applied its technologies to drug products in a range of therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition and respiratory.

Contact Information

Formerly Known As
American Home Products (Drug Delivery Business)
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • 123 Olympic Plaza
  • Fred. Roeskestraat
  • 1076 EE Amsterdam
  • Netherlands
+31 020
Primary Industry
Pharmaceuticals
Acquirer
Vertical(s)
Corporate Office
  • 123 Olympic Plaza
  • Fred. Roeskestraat
  • 1076 EE Amsterdam
  • Netherlands
+31 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eurand Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Eurand‘s full profile, request access.

Request a free trial

Eurand Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eurand Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Eurand‘s full profile, request access.

Request a free trial

Eurand Investments (2)

Eurand’s most recent deal was a Buyout/LBO with SourceCF for . The deal was made on 03-Dec-2007.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
SourceCF 03-Dec-2007 Buyout/LBO Specialty Retail
Immunex 20-May-1999 Convertible Debt Biotechnology
To view Eurand’s complete investments history, request access »

Eurand Exits (1)

Eurand’s most recent exit was on 20-May-1999 from Immunex. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Immunex 20-May-1999 Completed
To view Eurand’s complete exits history, request access »

Eurand FAQs

  • When was Eurand founded?

    Eurand was founded in 1969.

  • Where is Eurand headquartered?

    Eurand is headquartered in Amsterdam, Netherlands.

  • What is the size of Eurand?

    Eurand has 620 total employees.

  • What industry is Eurand in?

    Eurand’s primary industry is Pharmaceuticals.

  • Is Eurand a private or public company?

    Eurand is a Private company.

  • What is the current valuation of Eurand?

    The current valuation of Eurand is .

  • What is Eurand’s current revenue?

    The current revenue for Eurand is .

  • How much funding has Eurand raised over time?

    Eurand has raised $104M.

  • Who are Eurand’s investors?

    Warburg Pincus has invested in Eurand.

  • When was Eurand acquired?

    Eurand was acquired on 11-Feb-2011.

  • Who acquired Eurand?

    Eurand was acquired by Aptalis Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process